Skip to Main Content

Paper Details

The safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in Chinese adults aged 18-59 years: A phase I randomized, double-blinded, controlled trial.
Vaccine
34
2021
N protein, S protein, SARS, SARS-CoV-2, cytotoxic T lymphocyte, fatigue, immune cells
Author NameAffiliation
Ying ZhangInstitute of Medical Biology, Chinese Academy of Medicine Sciences & Peking Union Medical College
Shan LuUniversity of Massachusetts Medical School
  • 1 - 2

Datasets

Release 1.2